Skip to main content

Advertisement

Table 1 Clinical and pathological characteristics of breast cancer patients

From: The prognostic significance of RUNX2 and miR-10a/10b and their inter-relationship in breast cancer

Characteristicsa N (%)
Age (mean ± SD and range) 59.2 ± 13.2 (35–102 yrs)
Gender  
  Male 1 (0.9%)
  Female 107 (99.1%)
Histology  
  Ductal 95 (88.0%)
  Other 13 (12.0%)
Grade  
  I 7 (6.6%)
  II 36 (34.0%)
  III 63 (59.4%)
Stage  
  0 3 (2.8%)
  I 34 (31.8%)
  II 46 (43.0%)
  III 24 (22.4%)
ER  
  Negative 48 (44.4%)
  Positive 60 (55.6%)
PR  
  Negative 40 (37.0%)
  Positive 68 (63.0%)
Her2  
  Negative 53 (49.1%)
  Positive 55 (50.9%)
Molecular subtype  
  Luminal A 36 (33.3%)
  Luminal B 38 (35.3%)
  ER-, PR-, Her2+ 17 (15.7%)
  ER-, PR-, Her2- 17 (15.7%)
Regional lymph node involvement  
  No 62 (58.5%)
  Yes 44 (41.5%)
Relapse  
  No 71 (65.7%)
  Yes 37 (34.3%)
RFS duration median (range) 54.6 (1.1 ~ 100.9 months)
Outcomes  
  Alive 100 (92.5%)
  Dead 8 (7.5%)
OS duration median (range) 63.2 (1.6 ~ 217.9 months)
  1. ER: estrogen receptor, PR: progesterone receptor, HER2: HER2/neu, RFS: relapse free survival, OS: overall survival.
  2. Status of ER and PR was classified as “Positive” when 10% of cells were stained; HER2 status was defined as “Positive” when Dako score was 2+ or 3 + .
  3. aClinical characteristics according to the sixth edition of the AJCC Cancer Staging Manual (2006).